Ulrika Harmenberg

4.3k total citations
57 papers, 1.7k citations indexed

About

Ulrika Harmenberg is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ulrika Harmenberg has authored 57 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 21 papers in Molecular Biology. Recurrent topics in Ulrika Harmenberg's work include Renal cell carcinoma treatment (27 papers), Renal and related cancers (15 papers) and Cancer Genomics and Diagnostics (14 papers). Ulrika Harmenberg is often cited by papers focused on Renal cell carcinoma treatment (27 papers), Renal and related cancers (15 papers) and Cancer Genomics and Diagnostics (14 papers). Ulrika Harmenberg collaborates with scholars based in Sweden, United Kingdom and United States. Ulrika Harmenberg's co-authors include Börje Ljungberg, Sven Lundstam, Per Lindblad, Andreas Thorstenson, Britta Wahrén, Saeed Dabestani, Bernard Escudier, Sten Nilsson, Per Sandström and Anders Ullén and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

Ulrika Harmenberg

56 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ulrika Harmenberg Sweden 23 1.0k 736 693 375 281 57 1.7k
Julia Wilkerson United States 20 713 0.7× 608 0.8× 501 0.7× 284 0.8× 208 0.7× 44 1.8k
Benjamin L. Maughan United States 22 1.4k 1.4× 915 1.2× 541 0.8× 707 1.9× 294 1.0× 167 2.1k
Faith E. Nathan United States 23 1.2k 1.1× 1.4k 1.9× 356 0.5× 317 0.8× 188 0.7× 45 2.1k
Penelope A. Bradbury Canada 29 1.1k 1.1× 1.1k 1.5× 604 0.9× 419 1.1× 99 0.4× 112 2.0k
Christos E. Kyriakopoulos United States 19 1.1k 1.1× 780 1.1× 386 0.6× 346 0.9× 405 1.4× 84 2.0k
Tina Cheng Canada 14 1.7k 1.6× 1.0k 1.4× 1.0k 1.5× 633 1.7× 90 0.3× 39 2.3k
Vinod Ganju Australia 24 906 0.9× 2.0k 2.7× 655 0.9× 447 1.2× 123 0.4× 94 2.7k
Delphine Borchiellini France 22 1.2k 1.1× 986 1.3× 639 0.9× 458 1.2× 104 0.4× 89 1.8k
Maria Błasińska-Morawiec Poland 17 897 0.9× 1.7k 2.3× 364 0.5× 337 0.9× 88 0.3× 37 2.5k
Eckart Laack Germany 23 2.2k 2.2× 2.0k 2.7× 619 0.9× 408 1.1× 169 0.6× 61 3.0k

Countries citing papers authored by Ulrika Harmenberg

Since Specialization
Citations

This map shows the geographic impact of Ulrika Harmenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrika Harmenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrika Harmenberg more than expected).

Fields of papers citing papers by Ulrika Harmenberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulrika Harmenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrika Harmenberg. The network helps show where Ulrika Harmenberg may publish in the future.

Co-authorship network of co-authors of Ulrika Harmenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Ulrika Harmenberg. A scholar is included among the top collaborators of Ulrika Harmenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrika Harmenberg. Ulrika Harmenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tong, Le, Veronika Kremer, Shiyong Neo, et al.. (2025). Cellular and secretome profiling uncover immunological biomarkers in the prognosis of renal cell carcinoma patients. OncoImmunology. 14(1). 2481109–2481109. 1 indexed citations
2.
3.
Liu, Lisa L., et al.. (2023). Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature. Journal for ImmunoTherapy of Cancer. 11(3). e005841–e005841. 46 indexed citations
4.
Sundqvist, Pernilla, Ulrika Harmenberg, Mikael Hellström, et al.. (2022). Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease—A National Register Study. European Urology Open Science. 39. 22–28. 9 indexed citations
5.
Kaur, Gurjeet, Elin Sjöberg, Lars Egevad, et al.. (2021). Nuclear and stromal expression of Manic fringe in renal cell carcinoma. Experimental and Molecular Pathology. 122. 104667–104667. 6 indexed citations
6.
Lindblad, Per, Ulrika Harmenberg, Sven Lundstam, et al.. (2020). The renal cell cancer database Sweden (RCCBaSe) – a new register-based resource for renal cell carcinoma research. Scandinavian Journal of Urology. 54(3). 235–240. 9 indexed citations
7.
8.
Sjöberg, Elin, John Lövrot, Artur Mezheyeuski, et al.. (2018). A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis. British Journal of Cancer. 119(7). 840–846. 44 indexed citations
9.
Lindskog, Magnus, Rickard Sandin, Jan Kowalski, et al.. (2017). Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations. Urologic Oncology Seminars and Original Investigations. 35(9). 541.e15–541.e22. 22 indexed citations
10.
Powles, T.B., Bernard Escudier, Paul de Souza, et al.. (2016). Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial. Annals of Oncology. 27. vi284–vi284. 1 indexed citations
11.
Thorstenson, Andreas, Ulrika Harmenberg, Per Lindblad, Börje Ljungberg, & Sven Lundstam. (2015). Impact of quality indicators on adherence to National and European guidelines for renal cell carcinoma. Scandinavian Journal of Urology. 50(1). 2–8. 26 indexed citations
12.
Peng, Zheng, Lambert Skoog, Henrik Hellborg, et al.. (2014). An expression signature at diagnosis to estimate prostate cancer patients’ overall survival. Prostate Cancer and Prostatic Diseases. 17(1). 81–90. 33 indexed citations
13.
Harmenberg, Ulrika, Per Sandström, Sven Lundstam, et al.. (2013). Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008). British Journal of Cancer. 108(7). 1541–1549. 79 indexed citations
14.
15.
Harmenberg, Ulrika, Freddie C. Hamdy, Anders Widmark, Bo Lennernäs, & Sten Nilsson. (2011). Curative radiation therapy in prostate cancer. Acta Oncologica. 50(sup1). 98–103. 14 indexed citations
16.
Ingvarsson, Johan, Christer Wingren, Anders Carlsson, et al.. (2008). Detection of pancreatic cancer using antibody microarray‐based serum protein profiling. PROTEOMICS. 8(11). 2211–2219. 96 indexed citations
17.
Österborg, Anders, Eva Halapi, Jeanette Lundin, et al.. (1997). Clonal CD8+ and CD52– T cells are induced in responding B cell lymphoma patients treated with Campath‐1H* (anti‐CD52). European Journal Of Haematology. 58(1). 5–13. 28 indexed citations
18.
19.
Mellstedt, Håkan, Jan‐Erik Frödin, Peter Ragnhammar, et al.. (1989). The clinical use of monoclonal antibodies, MAb 17-1A, in the treatment of patients with metastatic colorectal carcinoma. Medical Oncology and Tumor Pharmacotherapy. 6(1). 99–107. 12 indexed citations
20.
Harmenberg, Ulrika, et al.. (1989). Significance of Alkaline Phosphatase Isozymes in the Monitoring of Patients with Colorectal Carcinoma. Tumor Biology. 10(5). 225–231. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julia Wilkerson Breakdown of academic impact, for papers by Benjamin L. Maughan Breakdown of academic impact, for papers by Faith E. Nathan Breakdown of academic impact, for papers by Penelope A. Bradbury Breakdown of academic impact, for papers by Christos E. Kyriakopoulos Breakdown of academic impact, for papers by Tina Cheng Breakdown of academic impact, for papers by Vinod Ganju Breakdown of academic impact, for papers by Delphine Borchiellini Breakdown of academic impact, for papers by Maria Błasińska-Morawiec Breakdown of academic impact, for papers by Eckart Laack
Rankless by CCL
2026